Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-MYC)1Lach
• Allele Name: transgene insertion 1, Lewis A Chodosh
• Allele ID: MGI:3531157
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(MMTV-KRAS*G12V)3025Mrl/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0	involves: C57BL/6 * FVB/N * SJL	MGI:5827761
cx2	Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0	involves: FVB	MGI:5432250
cx3	Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0 Tg(tetO-MYC)1Lach/0	involves: FVB/N	MGI:5827758

Genotype
MGI:5827761

cx1

• Allelic Composition: Tg(MMTV-KRAS*G12V)3025Mrl/0; Tg(MMTV-rtTA)1Lach/0; Tg(tetO-MYC)1Lach/0
• Genetic Background: involves: C57BL/6 * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

integument

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:133578

Genotype
MGI:5432250

cx2

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-MYC)1Lach/0
• Genetic Background: involves: FVB

neoplasm

increased mammary gland tumor incidence ( J:67498 , J:133578 )

♀ • chronically doxycycline induced females develop mammary tumors with high penetrance (86%) following an average of 22 weeks of induction (J:67498)

♀ • mice fed doxycycline after weaning develop solitary mammary tumors with a median latency of 26 weeks after induction (J:133578)

increased mammary adenocarcinoma incidence ( J:67498 )

♀ • mammary tumors in chronically doxycycline induced females are invasive mammary adenocarcinomas

♀ • withdrawal of doxycycline from chronically induced tumor-bearing mutants results in rapid regression of a subset of invasive mammary adenocarcinomas (14 days) but another subset of tumors decrease in size but then resume growth

♀ • tumors that continue to grow after doxycycline removal show undetectable expression of the MYC transgene but increased endogenous Myc expression and exhibit mutations in Kras or Nras

integument

increased mammary gland epithelial cell proliferation ( J:67498 )

♀ • mammary epithelium of mutants induced with doxycycline exhibits increased proliferation

abnormal mammary gland morphology ( J:67498 )

♀ • mammary glands of mutants induced with doxycycline for 4 months exhibit atypical lobuloalveolar growths (dysplasia)

abnormal mammary gland epithelium morphology ( J:67498 )

♀ • non-tumor bearing mammary glands of mutants induced with doxycycline for 30 weeks (chronically induced) exhibit numerous epithelial hyperplasts and dysplasts, however when doxycycline is withdrawn for 12 weeks, most epithelial ducts appear normal

increased mammary gland tumor incidence ( J:67498 , J:133578 )

♀ • chronically doxycycline induced females develop mammary tumors with high penetrance (86%) following an average of 22 weeks of induction (J:67498)

♀ • mice fed doxycycline after weaning develop solitary mammary tumors with a median latency of 26 weeks after induction (J:133578)

increased mammary adenocarcinoma incidence ( J:67498 )

♀ • mammary tumors in chronically doxycycline induced females are invasive mammary adenocarcinomas

♀ • withdrawal of doxycycline from chronically induced tumor-bearing mutants results in rapid regression of a subset of invasive mammary adenocarcinomas (14 days) but another subset of tumors decrease in size but then resume growth

♀ • tumors that continue to grow after doxycycline removal show undetectable expression of the MYC transgene but increased endogenous Myc expression and exhibit mutations in Kras or Nras

mammary gland hyperplasia ( J:67498 )

♀ • mammary glands of mutants induced with doxycycline for 30 days are hyperplastic

♀ • mammary glands of mutants induced with doxycycline for 4 months exhibit focal hyperplasia

increased mammary gland apoptosis ( J:67498 )

♀ • mammary epithelium of mutants induced with doxycycline exhibits increased apoptosis

endocrine/exocrine glands

increased mammary gland epithelial cell proliferation ( J:67498 )

♀ • mammary epithelium of mutants induced with doxycycline exhibits increased proliferation

abnormal mammary gland morphology ( J:67498 )

♀ • mammary glands of mutants induced with doxycycline for 4 months exhibit atypical lobuloalveolar growths (dysplasia)

abnormal mammary gland epithelium morphology ( J:67498 )

♀ • non-tumor bearing mammary glands of mutants induced with doxycycline for 30 weeks (chronically induced) exhibit numerous epithelial hyperplasts and dysplasts, however when doxycycline is withdrawn for 12 weeks, most epithelial ducts appear normal

increased mammary gland tumor incidence ( J:67498 , J:133578 )

♀ • chronically doxycycline induced females develop mammary tumors with high penetrance (86%) following an average of 22 weeks of induction (J:67498)

♀ • mice fed doxycycline after weaning develop solitary mammary tumors with a median latency of 26 weeks after induction (J:133578)

increased mammary adenocarcinoma incidence ( J:67498 )

♀ • mammary tumors in chronically doxycycline induced females are invasive mammary adenocarcinomas

♀ • withdrawal of doxycycline from chronically induced tumor-bearing mutants results in rapid regression of a subset of invasive mammary adenocarcinomas (14 days) but another subset of tumors decrease in size but then resume growth

♀ • tumors that continue to grow after doxycycline removal show undetectable expression of the MYC transgene but increased endogenous Myc expression and exhibit mutations in Kras or Nras

mammary gland hyperplasia ( J:67498 )

♀ • mammary glands of mutants induced with doxycycline for 30 days are hyperplastic

♀ • mammary glands of mutants induced with doxycycline for 4 months exhibit focal hyperplasia

increased mammary gland apoptosis ( J:67498 )

♀ • mammary epithelium of mutants induced with doxycycline exhibits increased apoptosis

cellular

increased mammary gland epithelial cell proliferation ( J:67498 )

♀ • mammary epithelium of mutants induced with doxycycline exhibits increased proliferation

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:67498 , J:133578

Genotype
MGI:5827758

cx3

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-Kras2)12Hev/0; Tg(tetO-MYC)1Lach/0
• Genetic Background: involves: FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133578 )

♀ • diffuse mammary hyperplasia is seen at 7 days after doxycycline administration, numerous tumor nodules are seen throughout the glandular tree at 14 days and confluent tumors are present at 21 days

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state within 2 weeks

♀ • solitary mammary tumors develop after withdrawal of doxycycline in 20 of 36 mice at a median age of 53 weeks, indicating recurrent tumors

♀ • in the absence of doxycycline, only one of 31 mice develop a mammary tumor

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

integument

increased mammary gland tumor incidence ( J:133578 )

♀ • diffuse mammary hyperplasia is seen at 7 days after doxycycline administration, numerous tumor nodules are seen throughout the glandular tree at 14 days and confluent tumors are present at 21 days

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state within 2 weeks

♀ • solitary mammary tumors develop after withdrawal of doxycycline in 20 of 36 mice at a median age of 53 weeks, indicating recurrent tumors

♀ • in the absence of doxycycline, only one of 31 mice develop a mammary tumor

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

mammary gland hyperplasia ( J:133578 )

♀ • diffuse mammary hyperplasia is seen at 7 days after doxycycline administration

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:133578 )

♀ • diffuse mammary hyperplasia is seen at 7 days after doxycycline administration, numerous tumor nodules are seen throughout the glandular tree at 14 days and confluent tumors are present at 21 days

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state within 2 weeks

♀ • solitary mammary tumors develop after withdrawal of doxycycline in 20 of 36 mice at a median age of 53 weeks, indicating recurrent tumors

♀ • in the absence of doxycycline, only one of 31 mice develop a mammary tumor

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

mammary gland hyperplasia ( J:133578 )

♀ • diffuse mammary hyperplasia is seen at 7 days after doxycycline administration

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:114480